Indications
Transdermal drug delivery has become increasingly popular due to its significant advantages. Additionally, transdermal drugs reduce the risk of damage to the gastrointestinal system inherent to oral formulations, increase the likelihood of patient compliance, and provide continuous, stable administration.[1][2][3] Transdermal administration also avoids the hepatic first-pass metabolism that affects orally administered drugs.[4]
The fundamental principle of transdermal drug delivery involves the ability of the drug to pass through the skin into the systemic circulation. These drugs have a low molecular weight (<600 g/mol) and can pass through the epidermis before crossing into local blood vessels and entering the circulatory system. Additionally, the active drug must be chemically and physically stable, be metabolized in the skin, and have a low daily dose for patient comfort and adhesive propensity. There have only been a limited number of successful transdermal drugs with such specific properties.[2][5]
Some indications that transdermal medications have addressed since the 1970s include:
- Hypertension
- Local anesthesia
- Angina pectoris
- Motion sickness
- Pain
- Smoking control
- Migraine
- Major depressive disorder (MDD)
- Parkinson disease
- Alzheimer disease
- Attention-deficit hyperactivity disorder (ADHD)
Transdermal administration is generally safe and effective when used as directed.
FDA-Approved Indications
- Asenapine: Schizophrenia
- Buprenorphine: Pain [6]
- Clonidine: Hypertension
- Dextroamphetamine: ADHD [7]
- Donepezil: Alzheimer disease [8]
- Granisetron: Emesis
- Lidocaine: Pain
- Methylphenidate: ADHD
- Nicotine: Smoking cessation
- Nitroglycerin: Angina pectoris
- Oxybutynin: Overactive bladder
- Scopolamine: Motion sickness
- Rivastigmine: Alzheimer disease
- Rotigotine: Parkinson disease [9]
- Selegiline: MDD [10]
- Fentanyl: Pain (severe) [11][4]
Mechanism of Action
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
The greatest challenge for transdermal drug delivery is diffusing active substances through the barrier formed by the many layers of the skin. The outermost (and thickest) layer of the skin, the stratum corneum, contains numerous layers of keratin-heavy corneocytes. Additionally, the stratum corneum consists of 2 chemically different regions that must be accounted for when creating transdermal drugs. There is an aqueous region at the outer surface of the keratin filaments and a lipid matrix between the filaments that active medications must diffuse through to be effective.[12]
However, recent advancements have been made in the development of enhancement delivery methods for active drugs through the transdermal route. These methods are listed below.
- Microneedles: These are tiny needles that are either hollow or solid and filled with the desired drug. The microneedles pierce through the stratum corneum without causing a painful sensation. This method's advantages include painless delivery and delivering compounds with a higher molecular weight.[13][14]
- Iontophoresis: This method uses electrical driving force to drive charged particles across the stratum corneum via electrophoresis. Through this process, a persistent low-voltage current enables the diffusion of substances across the stratum corneum. An electrical current can control the drug delivery rate under the control of a preprogrammed microprocessor unit or the patient.
- Thermal poration: Applying heat to the skin creates small pores that allow the easy diffusion of molecular substances across the stratum corneum.
- Electroporation: Applying a high electrical voltage to the stratum corneum also creates small pores through which molecular substances can diffuse.
- Conventional enhancers: A chemical substance applied first to the skin to increase the stratum corneum's permeability or change the active drug's thermodynamics.
- Ultrasound: The application of sound waves to disrupt the stratum corneum and increase its permeability.[1][2][15][16]
Administration
Transdermal patches should only be placed after a proper physical examination and consideration of any associated comorbidities. The following steps are a general overview of administering a transdermal patch.
- Proper disinfecting and cleaning of skin where the patch is applied
- Application of patch in the desired area
- A follow-up appointment to ensure that the patient experiences no adverse skin reactions
- Proper adherence to the guidelines of the transdermal patch for future use
The administration of transdermal patches varies based on the drug administered.[17] However, certain steps generally apply to all transdermal patches:
- The patient should clean and disinfect the area where they will apply the patch with clear water, patting it until it is completely dry. They should avoid using any soaps, alcohols, lotions, or oils immediately before applying the patch.
- They should open the pouch containing the patch and remove it from the pouch. Then, peel off both parts of the protective liner from the back of the patch, being careful not to touch the adhesive side.
- The patient should then immediately press the adhesive side of the patch onto their skin with the palm of their hand.
- Hold or press the patch firmly for at least 30 seconds, ensuring the patch sticks well to the skin, especially at the edges.
- If the patch does not adhere well or becomes loose following application, they can use first-aid tape to tape the edges to their skin. If the patch still fails to adhere well to the skin, they can use see-through dressings but should not cover the patch with any other type of bandage or tape.
- If a patch falls off before it is time to remove it, the patient must dispose of it properly and apply a new patch, following the same dosing interval as the original patch. In such cases, it is advisable to contact their clinician's office or pharmacist.
- Following the successful application of the patch, the patient should wash their hands with water immediately.
- When it is time to change the patch, the patient peels off the old patch and applies the new patch to a different area of the skin.
- After removing the patch, the patient should fold it over with the adhesive sides together and dispose of it properly.
The patient should select different sites each time the patch is applied to avoid skin irritation. Some patches are only meant to be worn for part of a day (eg, 12 hours), while others are intended for several days. For example, fentanyl patches are worn for 72 hours and then removed and reapplied.
Patients must understand that a removed patch can still contain enough medication to cause problems if they do not dispose of it properly. This is especially concerning if children have access to discarded patches. Patches should not be used if damaged or torn, as this may cause a "dose dumping" phenomenon where the medication is dispensed more rapidly than intended. If patients have any questions about their transdermal patches, they should contact their clinician or pharmacist immediately.
Adverse Effects
The typical adverse effects caused by transdermal drug delivery include adverse cutaneous reactions. Transdermal patches are the most common delivery method for active substances, but they can irritate the skin and cause pruritis, burns, and redness in the surrounding area.[5] Additionally, allergic reactions are reported for all types of patches on the skin due to the active substance administered. The most common skin reactions include contact dermatitis and allergic contact dermatitis, usually caused by the drug or the patch, including adhesives and excipients.[18][19]
Applying multiple patches when only a single is prescribed or leaving a patch in place for longer than directed can lead to excessive drug absorption and increase the risk of overdose and toxicity.
Contraindications
Transdermal drug delivery is contraindicated for patients with the following conditions.[20]
- Allergies to the active substance contained in the transdermal patch
- Essential fatty acid deficiency
- Psoriasis
- Ichthyosis
- Atopic dermatitis
- Increased ultraviolet radiation exposure
- Premature neonate
- Pregnant women (depending on the administered drug)
Monitoring
The most significant issue associated with transdermal drug delivery is the likelihood of skin irritation caused by penetration enhancement techniques and the transdermal patch itself. In response, models have been developed to predict the likelihood of skin irritation due to drug or vessel interaction using solubility and skin irritation studies using the PII test to detect redness or swelling 24 hours after administering the patch.[12][21]
Toxicity
The toxicity of the transdermal patch depends on the active substance administered through transdermal drug delivery and whether the patient properly follows administration directions. For specific management, please refer to the individual product labeling of drug delivery systems.
Enhancing Healthcare Team Outcomes
Proper drug administration requires interprofessional effort from various healthcare professionals, including clinicians, pharmacists, nurses, and residents. Numerous drug-related problems result in medication-related harm and low-quality healthcare for patients without appropriate regulation and administration techniques. To properly deliver a drug via transdermal patches, the following steps are necessary:
- A proper physical examination and regular updating of the patient's medical history by the prescribing clinician are essential for ensuring safe and effective treatment.
- Consult with the pharmacist about the appropriate drug based on the patient symptoms and history.
- Consult with a clinician if there are any concerns about a transdermal patch.
- The patient should go to the nearest emergency department should a life-threatening condition arise.
Techniques such as face-to-face interviews enhance communication between healthcare professionals and the cohesiveness between pharmacists, primary care physicians, and surgeons in drug-related healthcare. These techniques also include reinforcement of patient counseling points to ensure proper administration and contacting the prescriber if the patient cannot perform self-administration properly. Ultimately, these techniques allow for an amplified patient-centered approach.[22][23] With interprofessional coordination and information sharing during patient care, transdermal medications can significantly benefit the appropriate patient population, resulting in improved medication adherence and better outcomes. Communication among clinicians, pharmacists, and nurses is crucial to decreasing potential adverse effects, improving disease course and quality of life, and improving patient outcomes related to transdermal medications.
References
Prausnitz MR, Langer R. Transdermal drug delivery. Nature biotechnology. 2008 Nov:26(11):1261-8. doi: 10.1038/nbt.1504. Epub [PubMed PMID: 18997767]
Walter JR, Xu S. Therapeutic transdermal drug innovation from 2000 to 2014: current status and outlook. Drug discovery today. 2015 Nov:20(11):1293-9. doi: 10.1016/j.drudis.2015.06.007. Epub 2015 Jun 23 [PubMed PMID: 26116094]
Karve T, Dandekar A, Agrahari V, Melissa Peet M, Banga AK, Doncel GF. Long-acting transdermal drug delivery formulations: Current developments and innovative pharmaceutical approaches. Advanced drug delivery reviews. 2024 Jul:210():115326. doi: 10.1016/j.addr.2024.115326. Epub 2024 Apr 30 [PubMed PMID: 38692457]
Wong WF, Ang KP, Sethi G, Looi CY. Recent Advancement of Medical Patch for Transdermal Drug Delivery. Medicina (Kaunas, Lithuania). 2023 Apr 17:59(4):. doi: 10.3390/medicina59040778. Epub 2023 Apr 17 [PubMed PMID: 37109736]
Hupfeld S, Gravem H. [Transdermal therapeutic systems for drug administration]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 2009 Mar 12:129(6):532-3. doi: 10.4045/tidsskr.09.33349. Epub [PubMed PMID: 19282891]
Wong SSC, Chan TH, Wang F, Chan TCW, Ho HC, Cheung CW. Analgesic Effect of Buprenorphine for Chronic Noncancer Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Anesthesia and analgesia. 2023 Jul 1:137(1):59-71. doi: 10.1213/ANE.0000000000006467. Epub 2023 Jun 16 [PubMed PMID: 36988663]
Level 1 (high-level) evidenceEiland LS, Gildon BL. Diagnosis and Treatment of ADHD in the Pediatric Population. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2024 Apr:29(2):107-118. doi: 10.5863/1551-6776-29.2.107. Epub 2024 Apr 8 [PubMed PMID: 38596418]
Larkin HD. First Donepezil Transdermal Patch Approved for Alzheimer Disease. JAMA. 2022 May 3:327(17):1642. doi: 10.1001/jama.2022.6662. Epub [PubMed PMID: 35503362]
Sun W, Wang Q, Yang T, Feng C, Qu Y, Yang Y, Li C, Sun Z, Asakawa T. A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2022 Oct:43(10):5821-5837. doi: 10.1007/s10072-022-06159-9. Epub 2022 Jun 13 [PubMed PMID: 35691972]
Level 1 (high-level) evidenceRossano F, Caiazza C, Sobrino A, Solini N, Vellucci A, Zotti N, Fornaro M, Gillman K, Cattaneo CI, Van den Eynde V, Birkenhager TK, Ruhé HG, Stahl S, Iasevoli F, de Bartolomeis A. Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2023 Jul:72():60-78. doi: 10.1016/j.euroneuro.2023.03.012. Epub 2023 Apr 21 [PubMed PMID: 37087864]
Level 1 (high-level) evidenceArdila CM, Jiménez-Arbeláez GA, Vivares-Builes AM. Perioperative analgesic efficacy and adverse events of fentanyl in dentistry: A systematic review. Oral diseases. 2024 Jul:30(5):2807-2819. doi: 10.1111/odi.14773. Epub 2023 Oct 13 [PubMed PMID: 37837245]
Level 1 (high-level) evidenceBenson HA. Transdermal drug delivery: penetration enhancement techniques. Current drug delivery. 2005 Jan:2(1):23-33 [PubMed PMID: 16305405]
Tian R, Wang X, Li Y, Zhang L, Wen X. Application of microneedling in photodynamic therapy: A systematic review. Photodiagnosis and photodynamic therapy. 2024 Apr:46():104016. doi: 10.1016/j.pdpdt.2024.104016. Epub 2024 Feb 16 [PubMed PMID: 38367923]
Level 1 (high-level) evidenceMeng F, Qiao X, Xin C, Ju X, He M. Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2024:27():12434. doi: 10.3389/jpps.2024.12434. Epub 2024 Mar 20 [PubMed PMID: 38571937]
Level 2 (mid-level) evidenceTiwary AK, Sapra B, Jain S. Innovations in transdermal drug delivery: formulations and techniques. Recent patents on drug delivery & formulation. 2007:1(1):23-36 [PubMed PMID: 19075872]
Subedi RK, Oh SY, Chun MK, Choi HK. Recent advances in transdermal drug delivery. Archives of pharmacal research. 2010 Mar:33(3):339-51. doi: 10.1007/s12272-010-0301-7. Epub 2010 Mar 30 [PubMed PMID: 20361297]
Level 3 (low-level) evidenceLeppert W, Malec-Milewska M, Zajaczkowska R, Wordliczek J. Transdermal and Topical Drug Administration in the Treatment of Pain. Molecules (Basel, Switzerland). 2018 Mar 17:23(3):. doi: 10.3390/molecules23030681. Epub 2018 Mar 17 [PubMed PMID: 29562618]
Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and pharmacology. British journal of pharmacology. 2015 May:172(9):2179-209. doi: 10.1111/bph.13059. Epub 2015 Mar 18 [PubMed PMID: 25560046]
Level 3 (low-level) evidenceRomita P, Foti C, Calogiuri G, Cantore S, Ballini A, Dipalma G, Inchingolo F. Contact dermatitis due to transdermal therapeutic systems: a clinical update. Acta bio-medica : Atenei Parmensis. 2018 Oct 26:90(1):5-10. doi: 10.23750/abm.v90i1.6563. Epub 2018 Oct 26 [PubMed PMID: 30889148]
Kalia YN, Merino V, Guy RH. Transdermal drug delivery. Clinical aspects. Dermatologic clinics. 1998 Apr:16(2):289-99 [PubMed PMID: 9589202]
Al Hanbali OA, Khan HMS, Sarfraz M, Arafat M, Ijaz S, Hameed A. Transdermal patches: Design and current approaches to painless drug delivery. Acta pharmaceutica (Zagreb, Croatia). 2019 Jun 1:69(2):197-215. doi: 10.2478/acph-2019-0016. Epub [PubMed PMID: 31259729]
Foppe van Mil JW, Westerlund T, Brown L, Chen TF, Henman M, Hersberger K, McElnay J, Schulz M. Medical care and drug-related problems: Do doctors and pharmacists speak the same language? International journal of clinical pharmacy. 2016 Apr:38(2):191-4. doi: 10.1007/s11096-016-0249-x. Epub 2016 Jan 21 [PubMed PMID: 26797769]
Foral PA, Anthone JM, Destache CJ, Vivekanandan R, Preheim LC, Gorby GL, Horne JM, Dobronski LA, Syed JJ, Mindru C, Ali MA, Ali KF, Neemann KA, Bittner MJ. Education and Communication in an Interprofessional Antimicrobial Stewardship Program. The Journal of the American Osteopathic Association. 2016 Sep 1:116(9):588-93. doi: 10.7556/jaoa.2016.116. Epub [PubMed PMID: 27571295]